Mental Health Care Is Shifting From Access to Outcomes. Here's What That Means for You

For roughly two decades, growth in mental health care meant one thing: more access. More people finding a therapist, more parity laws, more telehealth, more insurance coverage. A Health Affairs analysis of national spending data found that 87.3% of the growth in US mental health and substance use disorder spending between 2000 and 2021 came from more people entering treatment, not from treatment getting more expensive per person.¹ Access, not intensity, was the story.

Q1 2026 earnings from the largest public mental health companies suggest that story is running out of road, and a different one is starting.

What the numbers are actually saying

Across five public mental health businesses reporting Q1 2026 results, a consistent pattern emerged: growth is modest, rate increases are hard to find, and clinician productivity, not new client acquisition, is doing most of the work.²

LifeStance grew revenue 21% year over year, the fastest in the group, driven mostly by an 11% increase in clinician headcount and a 7% increase in visits per clinician, alongside modest 3% growth in revenue per visit. Talkspace grew payer revenue 28%, but that growth was entirely volume-driven: the implied rate per payer session actually declined roughly 2% year over year. Acadia's headline 5.6% increase in revenue per patient day included one-time state supplemental payments; once stripped out, underlying rate growth was closer to 2%, in line with the rest of the group. BetterHelp's consumer revenue fell 14% year over year, continuing a multi-year decline in the direct-to-consumer, cash-pay segment.

None of these are growth stories about expanding access into new populations. They're operational efficiency stories: get more sessions out of the clinicians you already have, hold rates roughly flat, and manage costs. That's a sustainable way to run a services business for a while. It is not a strategy that differentiates one player from another, and it's not a strategy payers are likely to keep funding indefinitely without something else in return.

The something else is outcomes

Here's the detail buried in the same earnings season that matters more than the headline growth numbers: multiple companies used their Q1 disclosures to publish or reference outcomes data for the first time. LifeStance cited a study of roughly 180,000 patients showing about three-quarters achieved clinically significant improvement in anxiety or depression. LifeStance's CEO explicitly tied this to payer contract conversations, describing "growing demand for high-quality mental healthcare" as a market dynamic the company is responding to, not just a talking point.²

This is not a coincidence, and it's not new to public companies. Payer behavioral health costs have been rising 10 to 20% annually in recent years, a rate widely described as unsustainable by the payers absorbing it.³ Faced with that cost curve, payers are shifting what they demand in return for continued investment, moving from utilization data (how many sessions did you deliver) toward outcomes evidence (did those sessions actually work). A market that spent two decades rewarding access is starting to reward proof of effectiveness instead.

The same shift shows up in policy. The current federal push toward deprescribing and reducing reliance on medication-first treatment for mental health conditions, alongside growing reimbursement for non-pharmacological approaches like neuromodulation, reflects a broader move away from measuring success by treatment volume and toward measuring it by durable, meaningful improvement.⁴ Access got people into the system. Outcomes are becoming the condition for staying funded within it.

What "strong outcome evidence" actually requires

It's tempting to read this shift as "just track PHQ-9 and GAD-7 scores and you're covered." That's necessary, but it's not sufficient, and it's worth being precise about why. A useful framework here, developed by researchers who've spent years advising digital health companies on evidence strategy, breaks defensible outcome claims into four interdependent parts:⁵

The problem is real, quantified, and specific to a defined population, not a generic statistic about mental health prevalence in general.

The population your evidence covers actually matches the population you're claiming to serve, not a broader or different group.

The solution can be shown to be what's actually driving the change, not natural symptom fluctuation, concurrent treatment, or simply the motivation that comes from enrolling in any program.

The outcomes are measured with validated instruments, at a clinically meaningful magnitude, and shown to persist rather than fade once the intervention window ends.

Weakness in any one of these undermines the others. A therapist or practice that can say "on average, our clients' PHQ-9 scores improved" has weaker evidence than one that can say "clients with moderate to severe depression at intake showed a clinically meaningful reduction in PHQ-9 scores by session six, sustained at three-month follow-up." The second version survives a skeptical payer, employer, or referral partner asking hard questions. The first often doesn't.

What this means if you're not a public company

None of this requires the infrastructure of a national marketplace. It requires three things any practice can start doing now, roughly in this order of priority:

Measure consistently, not sporadically. If PHQ-9, GAD-7, or another validated instrument is administered inconsistently, or only when a therapist remembers to, there's no defensible trend line to point to later. Consistency is what turns individual data points into evidence.

Track the trend, not just the score. A single PHQ-9 score tells a payer or referral partner almost nothing. A documented trajectory across a defined population, especially one that shows durability at follow-up rather than fading immediately, is what actually holds up under scrutiny.

Know which claim you're building toward. Trying to build airtight evidence across every possible assertion at once is unrealistic for any practice. The more useful approach is identifying the one or two claims that actually matter for your next twelve months (a specific payer contract, a referral partnership, a group practice's differentiation in a competitive local market) and making sure the evidence behind that specific claim is solid, even if evidence elsewhere is still thin.

The practices that get ahead of this

The market spent two decades competing on who could deliver access fastest and cheapest. That race has largely been run, and the returns from it are visibly compressing across every major public player. The practices, and platforms, that build the infrastructure to consistently measure and demonstrate real, durable improvement now are positioning for the market that's actually forming, not the one that's winding down.

Learn more about comprehensive clinical assessments beyond PHQ-9 and GAD-7, and how outcomes visibility is also the missing piece for mental health marketplaces trying to build defensible demand.

---

Citt.ai gives therapists and practices continuous, structured visibility into how clients are actually progressing between sessions, not just at intake and discharge. Explore assessment and progress tracking features.

Footnotes

1. Saloner, B., et al. (2025). US National Spending on Mental Health and Substance Use Disorder Treatment Driven by Case Growth, 2000–21. Health Affairs. doi.org/10.1377/hlthaff.2025.01351. ↩

2. Talkspace, LifeStance Health, Acadia Healthcare, and Teladoc Health (BetterHelp) Q1 2026 earnings releases and investor call transcripts, reporting periods ended March 31, 2026. ↩ ↩²

3. Payer behavioral health cost trend estimates of 10–20% annual growth are widely reported across health plan actuarial commentary and industry analysis of behavioral health benefit spend; precise figures vary by payer and market segment. ↩

4. US Department of Health and Human Services action plan on psychiatric prescribing practices and CMS reimbursement changes supporting non-pharmacological treatment access, announced May 2026. ↩

5. Framework adapted from published guidance on building scientific credibility in digital health, distinguishing problem, population, solution, and outcome evidence as interdependent foundations for defensible clinical claims. ↩